This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhong, L. Articles by Kurie, J. M. Search for Related Content PubMed PubMed Citation Articles by Zhong, L. Articles by Kurie, J. M.

Identification of Secreted Proteins that Mediate Cell-Cell Interactions in an In vitro Model of the Lung Cancer Microenvironment

¹ Department of Thoracic/Head and Neck Medical Oncology, The University of Texas-M. D. Anderson Cancer Center; ² Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas; ³ Institute of Bioinformatics, International Technology Park, Bangalore, India; ⁴ McKusick-Nathans Institute for Genetic Medicine, Department of Biological Chemistry, The Johns Hopkins University School of Medicine, Baltimore, Maryland; and ⁵ Department of Medicine, University of Virginia, Charlottesville, Virginia

Requests for reprints: Jonathan M. Kurie, Unit 432, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-6363; Fax: 713-792-1220; E-mail: jkurie{at}mdanderson.org.

Key Words: cytokines • lung cancer • microenvironment

Non–small cell lung cancer (NSCLC) cells with somatic mutations in K-ras recruit to the tumor a variety of cell types (hereafter collectively termed "stromal cells") that can promote or inhibit tumorigenesis by mechanisms that have not been fully elucidated. Here, we postulated that stromal cells in the tumor microenvironment alter the tumor cell secretome, including those proteins required for tumor growth and dissemination, and we developed an in vitro model to test this hypothesis. Coculturing a murine K-ras mutant lung adenocarcinoma cell line (LKR-13) with a murine lung stromal cell (macrophage, endothelial cell, or fibroblast) enhanced stromal cell migration, induced endothelial tube formation, increased LKR-13 cell proliferation, and regulated the secretion of proteins involved in angiogenesis, inflammation, cell proliferation, and epithelial-to-mesenchymal transition. Among these proteins, CXCL1 has been reported to promote NSCLC development, whereas interleukin-18 (IL-18) has an undefined role. Genetic and pharmacologic strategies to inhibit CXCL1 and IL-18 revealed that stromal cell migration, LKR-13 cell proliferation, and LKR-13 cell tumorigenicity required one or both of these proteins. We conclude that stromal cells enhanced LKR-13 cell tumorigenicity partly through their effects on the secretome of LKR-13 cells. Strategies to inhibit tumor/stromal cell interactions may be useful as therapeutic approaches in NSCLC patients. [Cancer Res 2008;68(17):7237–45]

This article has been cited by other articles:

				J. Yee, M. D. Sadar, D. D. Sin, M. Kuzyk, L. Xing, J. Kondra, A. McWilliams, S.F. P. Man, and S. Lam Connective Tissue-Activating Peptide III: A Novel Blood Biomarker for Early Lung Cancer Detection J. Clin. Oncol., June 10, 2009; 27(17): 2787 - 2792. [Abstract] [Full Text] [PDF]

				S. Dubey and C. A. Powell Update in Lung Cancer 2008 Am. J. Respir. Crit. Care Med., May 15, 2009; 179(10): 860 - 868. [Full Text] [PDF]